Liver Cancer Therapy
Jennerex and Green Cross agree to develop and commercialize JX-594 in South Korea
Published in Health Business Week, November 17th, 2006
Under the terms of this agreement, Green Cross will fund all development, regulatory, manufacturing, and commercialization activities in South Korea for JX-594 and will pay Jennerex a royalty on commercial sales in South Korea. As part of the agreement, Jennerex is responsible for the clinical supply of JX-594 and Green Cross will have options to manufacture JX-594 to the South Korean market.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2006-11-17)
More Articles from Health Business Week
- Accreditation
URAC releases pharmacy benefits management accreditation standards for comment - Acute Radiation Syndrome
Hollis-Eden: Neumune mitigates ARS and healthcare-associated infections - Advanced Squamous Cell Carcinoma
Taxotere receives U.S. FDA approval for treatment for patients with head and neck cancer - Aesthetic Medicine
Isolagen and U.S. FDA reach agreement on phase III protocol design for wrinkle therapy - Allergy & Immunology
Allergic disease takes heavy toll on children's health and quality of life - Allergy & Immunology
U.S. FDA approves Allegra Oral Suspension for seasonal pediatric allergies, idiopathic urticaria - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
